Chitosan can favorably modulate plasma lipids, but the available data are not conclusive. We evaluated the effect of chitosan on plasma lipids and lipoproteins in 28 patients with plasma triglyceride levels >150 mg/dL (mean age: 63 ± 12 years), not taking other lipid-lowering agents. All patients received a chitosan derived from fungal mycelium (Xantonet, Bromatech, Italy) at a fixed dose of 125 mg/d in addition to their current medications for 4 months. Polyacrylamide gel electrophoresis was used to measure low-density lipoprotein (LDL) subclasses. After treatment, total cholesterol reduced by 8%, LDL cholesterol by 2%, and triglycerides by 19%, with a concomitant 14% increase in high-density lipoprotein cholesterol. We also found a beneficial effect of chitosan on LDL subclasses, with a significant increase in LDL-2 particles (from 37 ± 8% to 47 ± 8%, P = .0001) and a decrease (although not significant) in atherogenic small, dense LDL. Whether these findings may affect cardiovascular risk remains to be established in future studies.
OrmrodDJHolmesCCMillerTE. Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis. Atherosclerosis. 1998;138(2):329–334.
2.
NaussJLThompsonJLNagyuvaryJ. The binding of micellar lipids to chitosan. Lipids. 1983;18(10):714–719.
3.
ErnstEPittlerMH. A metaanalysis of chitosan for body weight reduction. Perfusion. 1998;11(11):461–465.
4.
MajetiNVRavi KumarMNV. A review of chitin and chitosan applications. React Funct Polym. 2000;46(1):1–27.
5.
GallaherDDGallaherCMMahrtGJ. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J Am Coll Nutr. 2002;21(5):428–433.
6.
RaySD. Potential aspects of chitosan as pharmaceutical excipient. Acta Pol Pharm. 2011;68(5):619–622.
7.
AusarSFMorcilloMLeónAE. Improvement of HDL- and LDL-cholesterol levels in diabetic subjects by feeding bread containing chitosan. J Med Food. 2003;6(4):397–399.
8.
TaiTSSheuWHLeeWJYaoHTChiangMT. Effect of chitosan on plasma lipoprotein concentrations in type 2 diabetic subjects with hypercholesterolemia. Diabetes Care. 2000;23(11):1703–1704.
9.
BakerWLTerciusAAngladeMWhiteCMColemanCI. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann Nutr Metab. 2009;55(4):368–374.
10.
WangDHanJYuY. Chitosan oligosaccharide decreases very-low-density lipoprotein triglyceride and increases high-density lipoprotein cholesterol in high-fat-diet-fed rats. Exp Biol Med (Maywood). 2011;236(9):1064–1069.
11.
RizzoMMikhailidisDP. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des. 2011;17(33):3608–3610.
12.
GrundySMCleemanJIDanielsSR; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752.
13.
AllainCCPoonLSChanCSRichmondWFuPC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470–475.
14.
NägeleUHägeleEOSauerG. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984;22(2):165–174.
15.
WarnickGRNguyenTAlbersJJ. Comparison of improved precipitation methods for quantification of high density lipoprotein cholesterol. Clin Chem. 1985;31(2):217–222.
16.
HoefnerDMHodelSDO'BrienJF. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001;47(2):266–274.
17.
MikhailidisDPElisafMS, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
18.
KalogirouMTsimihodimosVGaziI. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007;23(5):1169–1176.
19.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
20.
MikhailidisDPElisafMS, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–532.
21.
RizzoMBerneisK. Should we measure routinely the LDL peak particle size?Int J Cardiol. 2006;107(2):147–151.
22.
BjornhedenTBabyiABondjersGWiklundO. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 1996;123(1-2):43–56.
23.
CamejoGLopezALopezFQuinonesJ.Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis. 1985;55(1):93–105.
24.
TribbleDLRizzoMChaitALewisDMBlanchePJKraussRM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med. 2001;110(2):103–110.
25.
EgrasAMHamiltonWRLenzTLMonaghanMS. An evidence-based review of fat modifying supplemental weight loss products. J Obes. 2011;2011:7. doi:10.1155/2011/297315.
26.
SwislockiALSiegelDJialalI. Pharmacotherapy for the metabolic syndrome. Curr Vasc Pharmacol. 2012;10(2):187–205.
27.
HsiehYLYaoHTChengRSChiangMT. Chitosan reduces plasma adipocytokines and lipid accumulation in liver and adipose tissues and ameliorates insulin resistance in diabetic rats. J Med Food. 2012;15(5):453–460.
28.
LiuXZhiXLiuYWuBSunZShenJ.Effect of chitosan, O-carboxymethyl chitosan, and N-[(2-hydroxy-3-N,N-dimethyl-hexadecyl ammonium)propyl] chitosan chloride on overweight and insulin resistance in a murine diet-induced obesity. J Agric Food Chem. 2012;60(13):3471–3476.
29.
ZhouGDLiMRZhangJ. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand J Gastroenterol. 2008;43(11):1371–1377.
30.
BornfeldtKETabasI. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575–585.
31.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?Curr Vasc Pharmacol. 2011;9(6):698–705.
32.
YangYYTsaiTHHuangYTLeeTYChanCCLeeKCLinHC. Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats. Hepatology. 2012;55(5):1540–1550.
33.
KshatriyaSReamsGPSpearRMFreemanRHDietzJRVillarrealD. Obesity hypertension: the emerging role of leptin in renal and cardiovascular dyshomeostasis. Curr Opin Nephrol Hypertens. 2010;19(1):72–78.
34.
KatsikiNYovosJGGotzamani-PsarrakouAKaramitsosDT. Adipokines and vascular risk in type 2 diabetes mellitus. Angiology. 2011;62(8):601–604.
35.
AthyrosVGTziomalosKKaragiannisAAnagnostisPMikhailidisDP. Should adipokines be considered in the choice of the treatment of obesity-related health problems?Curr Drug Targets. 2010;11(1):122–135.
36.
KatsikiNMikhailidisDPGotzamani-PsarrakouAYovosJGKaramitsosD. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011;15(4):401–420.
37.
KatsikiNNikolicDMontaltoGBanachMMikhailidisDPRizzoM. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013;19(17):3124–3131.
38.
RizzoMRizviAASpinasGARiniGBBerneisK.Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors. Expert Opin Investig Drugs. 2009;18(10):1495–1503.
39.
RizzoMNikolicDBanachM. The effects of liraglutide on glucose, inflammatory markers, and lipoprotein metabolism: current knowledge and future perspectives. Clin Lipidol. 2013;8(2):173–181.
